Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 18, Number 4—April 2012

Comparison of Escherichia coli ST131 Pulsotypes, by Epidemiologic Traits, 1967–2009

James R. JohnsonComments to Author , Marie-Hélène Nicolas-Chanoine, Chitrita DebRoy, Mariana Castanheira, Ari Robicsek, Glen Hansen, Scott Weissman, Carl Urban, Joanne Platell, Darren Trott, George Zhanel, Connie Clabots, Brian D. Johnston, Michael A. Kuskowski, and the MASTER Investigators
Author affiliations: Veterans Affairs Medical Center, Minneapolis, Minnesota, USA (J.R. Johnson, C. Clabots, B.D. Johnston, M.A. Kuskowski); University of Minnesota, Minneapolis (J.R. Johnson, B.D. Johnston, M.A. Kuskowski); Hôpital Beaujon, Clichy, France (M.-H. Nicolas-Chanoine); The Pennsylvania State University, College Park, Pennsylvania, USA (C. DebRoy); JMI Laboratories, North Liberty, Iowa, USA (M. Castanheira); NorthShore University HealthSystem, Evanston, Illinois, USA (A. Robicsek); Hennepin County Medical Center, Minneapolis (G. Hansen); University of Washington, Seattle, Washington, USA (S. Weissman); New York Hospital Queens, Flushing, New York, USA (C. Urban); New York University School of Medicine, New York, New York, USA (C. Urban); University of Queensland, Brisbane, Queensland, Australia (J. Platell); University of Adelaide, Adelaide, South Australia, Australia (D. Trott); University of Manitoba, Winnipeg, Manitoba, Canada (G. Zhanel)

Main Article

Table 8

Results of multivariable logistic regression analysis for predictors of selected pulsotype categories among 579 Escherichia coli ST131 isolates, 1967–2009*

Outcome variable, significant predictor variables† Odds ratio (95% CI) p value Nagelkerke R2 for model‡
Pulsotype 968 0.18
Human source 0.20 (0.09–0.46) <0.001
FQ-R 55.04 (10.63–285.03) <0.001
ESBL production 0.63 (0.41–0.90) 0.03
Pulsotype 800 0.31
Human source 10.61 (1.32–85.48) 0.03
FQ-R 46.50 (3.75–576.74) .003
ESBL production 0.10 (0.05–0.19) <0.001
Pulsotype 812 0.21
Year of isolation/submission 1.47 (1.07–2.03) 0.02
ESBL production 17.53 (4.02–76.07) <0.001
High-prevalence pulsotypes 0.16
Year of isolation/submission 1.09 (1.03–1.55) 0.003
FQ-R 4.04 (2.22–7.34) <0.001
ESBL production 0.47 (0.32–0.70) <0.001
Multiple-isolate pulsotypes 0.13
Year of isolation/submission 1.07 (1.02–1.13) 0.009
FQ-R 3.42 (1.76–6.66) <0.001
ESBL production 0.42 (0.24–0.71) 0.001

*ST, sequence type; FQ-R, fluoroquinolone resistance/resistant; ESBL, extended-spectrum β-lactamase; high-prevalence pulsotypes, 12 pulsotypes that contained >6 isolates (>1% of population) each; multiple-isolate pulsotypes, 65 pulsotypes that contained >1 isolate each.
†Variables shown are those that yielded p values of <0.05. With 1 exception, each model included the following candidate predictor variables: human source (vs. other sources), US origin (vs. Canada or other international locale origin), year of isolation/submission, FQ-R, and ESBL production. All pulsotype 812 isolates were FQ-R; thus, FQ-R could not be included in that model.
‡Nagelkerke R2 provides an estimate of the total amount of variance accounted for by the model, i.e., the model's explanatory power. Values range from 0 (no explanatory power) to 1.0 (complete prediction).

Main Article

1MASTER (Macrorestriction Analysis of ST131 for Epidemiologic Research) Investigators who contributed data are listed at the end of this article.

Page created: March 15, 2012
Page updated: March 15, 2012
Page reviewed: March 15, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.